Jazz Enterprises Inc
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Jazz Enterprises Inc stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs EPS (TTM), CTXR P/E.
Implied fair value · at Jazz Enterprises Inc's multiple
Needs EPS (TTM) is negative, Jazz Enterprises Inc P/E.
Engine logicJazz Enterprises Incvalued onCTXR’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Jazz Enterprises Inc Latest annual filing · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
JAZZ ENTERPRISES INC · implied price per share
Reporting currency could not be verified.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Jazz Enterprises Inc · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
-0.06x
Net debt / EBITDA
Leverage against operating earnings
—
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
—
$41.71M
Total debt
Interest-bearing obligations outstanding
—
-$6.11M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
Jazz Enterprises Inc vs ZOM
Aquestive Therapeutics, Inc.
Jazz Enterprises Inc vs AQST
ACADIA PHARMACEUTICALS INC
Jazz Enterprises Inc vs ACAD
AMGEN INC
Jazz Enterprises Inc vs AMGN
GILEAD SCIENCES, INC.
Jazz Enterprises Inc vs GILD
AbbVie Inc.
Jazz Enterprises Inc vs ABBV
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.